Denver Man Continues Seven Summits Quest: Making History for...
Save One Life's Chris Bombardier will attempt to be the first person with hemophilia to scale Carstensz Pyramid, the highest peak in Oceania and the fifth mountain in his Seven Summits Quest.(PRWeb March 06, 2015)Read the full story at http://www.prweb.com/releases/2015/03/prweb12565783.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 6, 2015 Category: Pharmaceuticals Source Type: news

Hemophilia B: Lentiviral Vector Safe, Effective in DogsHemophilia B: Lentiviral Vector Safe, Effective in Dogs
Lentiviral vectors effectively delivered factor IX genes to dogs with hemophilia B, ameliorating symptoms; experiments in mice ruled out insertional mutagenesis. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 5, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Simoctocog alfa for haemophilia A: No suitable data
No added benefit can be derived from the dossier after the study of the use of Simoctocog alfa for haemophilia A. The duration of the direct comparative studies was too short and the study pool on one-arm studies with the comparator therapy was incomplete, experts say. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2015 Category: Science Source Type: news

Simoctocog alfa for haemophilia A: No suitable data
(Institute for Quality and Efficiency in Health Care) No added benefit can be derived from the dossier: The duration of the direct comparative studies was too short and the study pool on one-arm studies with the comparator therapy was incomplete. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2015 Category: Global & Universal Source Type: news

No Evolution Deniers in the White House
The 2016 presidential campaign is already upon us and the debate is heating up over an unexpected issue -- the theory of evolution. Of course, in an ideal world, evolution would never really become a campaign issue. But the anti-science wing of the Republican Party continues to voice skepticism. Apologists for this wing would dearly like to distract the media and the voting public from what is, frankly, a national if not a global embarrassment. In truth, the President of the United States needs to be scientifically literate. For the federal government has an important role to play and it is a role that will only grow larg...
Source: Science - The Huffington Post - February 19, 2015 Category: Science Source Type: news

Biogen Idec to add 100 jobs in RTP
Multiple sclerosis and hemophilia drug maker Biogen Idec (Nasdaq: BIIB) will add 100 workers to its operations in Research Triangle Park. The announcement comes on the same day Biogen Idec reported 2014 revenues of $9.7 billion, a 40 percent increase from 2013, and adds to the 1,300 workers already employed by the biotechnology company in the Triangle. Biogen also produces treatments for hemophilia and has grown revenue and employment by more than 50 percent over the past three years and is expecting… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 29, 2015 Category: Pharmaceuticals Authors: Jason deBruyn Source Type: news

17.12.14: Not intended for U.S. and UK Media
Bayer Submits Application for U.S. FDA Approval for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Childrenmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 18, 2014 Category: Pharmaceuticals Source Type: news

Bayer Submits Application for U.S. FDA Approval for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - December 17, 2014 Category: Pharmaceuticals Source Type: news

Pioneer Award winners Katherine High, Amit Nathwani, Arthur Nienhuis, and Andrew Davidoff honored
(Mary Ann Liebert, Inc./Genetic Engineering News) Recognized for her pioneering work to develop gene therapy for hemophilia spanning several decades, taking it from the laboratory into human clinical trials, is Katherine A. High, M.D., Spark Therapeutics. Also recognized for their demonstration of successful clinical applications of adeno-associated virus vector-based gene therapy for hemophilia B are Amit C. Nathwani, M.D., Ph.D., UCL Cancer Institute, and Arthur W. Nienhuis, M.D., and Andrew M. Davidoff, M.D., St. Jude Children's Research Hospital. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 17, 2014 Category: Global & Universal Source Type: news

Pfizer Bets on Gene Therapy with Spark Therapeutics Deal
Spark gene therapy biotech will partner with established market leader Pfizer to develop a potential new treatment paradigm for hemophilia B. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 9, 2014 Category: Pharmaceuticals Source Type: news

Roche presents data for hemophilia A therapy ACE910
Roche presented data from a first-in-patient study of the novel humanised bispecific antibody ACE910 (RG6013) in hemophilia A patients during the 56th American Society of Hematology (ASH) Annual Meeting. Results from the open-label phase I study, conducted by Chugai, showed once-weekly subcutaneous administration of ACE910 was well tolerated and possessed a promising efficacy profile in hemophilia A patients. (Source: Roche Investor Update)
Source: Roche Investor Update - December 9, 2014 Category: Pharmaceuticals Source Type: news

Gene Therapy Used to Treat Hemophilia
Experimental gene therapy improved symptoms for as long as 4 years in men with severe hemophilia. The study shows the potential for gene therapy to treat this and other disorders. (Source: NIH Research Matters)
Source: NIH Research Matters - December 8, 2014 Category: Research Source Type: news

Boston Children’s innovation chief Naomi Fried leaves for Biogen
Naomi Fried, Boston Children’s Hospital’s Chief Innovation Officer, is leaving the hospital to become Vice President of Medical Information, Innovation, and External Partnerships at Biogen Idec, MobiHealthNews has learned. “I have loved working at Boston Children’s, which is one of the finest organizations in the world,” she wrote in an email. “I feel grateful to […] (Source: mobihealthnews)
Source: mobihealthnews - December 8, 2014 Category: Information Technology Authors: Jonah Comstock Tags: Uncategorized Biogen digital health Biogen Idec Boston Children's Hospital hemophilia multiple sclerosis Naomi Fried Source Type: news

Bayer submits marketing authorisation application for haemophilia A product
Bayer HealthCare submitted an application for marketing authorisation to the European Medicines Agency (EMA) for BAY 81-8973, a recombinant Factor VIII (rFVIII) compound, for the treatment of haemophilia A in children and adults. BAY 81-8973 is a full-length recombinant Factor VIII that has demonstrated clinical evidence of efficacy when used for prophylaxis 2 or 3 times per week, with typical dosages. (1) Bayer plans to file BAY 81-8973 for approval in other countries in the coming months. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 5, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Haematology Patient care BAY 81-8973 blood coagulation proteins haemophilia a Latest News LEOPOLD II trial low-dose prophylaxis regimen recombinant Factor VIII Source Type: news

04.12.14: Not intended for U.S. and UK Media
Bayer Submits Marketing Authorization Application in Europe for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Childrenmehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - December 4, 2014 Category: Pharmaceuticals Source Type: news

Bayer Submits Marketing Authorization Application in Europe for Recombinant Factor VIII Product (BAY 81-8973) for the Treatment of Hemophilia A in Adults and Children (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - December 4, 2014 Category: Pharmaceuticals Source Type: news

Bayer to seek approval for new hemophilia drug by year-end
FRANKFURT (Reuters) - German drugmaker Bayer AG will file for regulatory approval of its experimental hemophilia drug Bay 81-8973 by the end of the year, it said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - December 2, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Innovaacom Program Leads Way in Addressing International Problem of...
Just Released Results from Innovaacom Program Show 94% of Physicians More Confident Treating and Communicating Best Practices for Hemophilia(PRWeb November 21, 2014)Read the full story at http://www.prweb.com/releases/2014/11/prweb12340489.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 21, 2014 Category: Pharmaceuticals Source Type: news

Gene therapy provides safe, long-term relief for patients with severe hemophilia B
Gene therapy has transformed life for men with a severe form of hemophilia B by providing a safe, reliable source of the blood clotting protein Factor IX that has allowed some to adopt a more active lifestyle, researchers report. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 20, 2014 Category: Science Source Type: news

Gene Therapy: Safe, Long-term Relief for Patients with Severe Hemophilia B
Gene therapy developed at St. Jude Children’s Research Hospital, University College London (UCL) and the Royal Free Hospital has transformed life for men with a severe form of hemophilia B by providing a safe, reliable source of the blood clotting protein Factor IX that has allowed some to adopt a more active lifestyle, researchers reported. The results appear in the November 20 edition of The New England Journal of Medicine. (Source: Disabled World)
Source: Disabled World - November 20, 2014 Category: Disability Tags: Health and Disability Source Type: news

Gene Therapy: Safe, Long-term Relief for Patients with Severe Hemophilia B
Gene therapy provides men with hemophilia B reliable relief from the bleeding disorder (Source: Disabled World)
Source: Disabled World - November 20, 2014 Category: Disability Tags: Health and Disability Source Type: news

Your NEJM Group Today: Rotation of the Liver, Gene Transfer & Hemophilia B, Utah Neurologist Opportunity (FREE)
By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 20, 2014 Category: Primary Care Source Type: news

Gene therapy found effective in hemophilia B
(Reuters Health) - Ten patients with severe hemophilia B have remained cured of the inherited bleeding disorder for as long as three years thanks to gene therapy, according to a new report on the technique in the New England Journal of Medicine. (Source: Reuters: Health)
Source: Reuters: Health - November 19, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Gene therapy provides safe, long-term relief for patients with severe hemophilia B
(St. Jude Children's Research Hospital) Gene therapy developed at St. Jude Children's Research Hospital, University College London and the Royal Free Hospital has transformed life for men with a severe form of hemophilia B by providing a safe, reliable source of the blood clotting protein Factor IX that has allowed some to adopt a more active lifestyle, researchers reported. The results appear in the November 20 edition of The New England Journal of Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 19, 2014 Category: Global & Universal Source Type: news

Gene therapy provides safe, long-term relief for patients with severe hemophilia B
Gene therapy pioneered by St. Jude Children’s Research Hospital, University College London and the Royal Free Hospital provides provided men with hemophilia B reliable relief from the bleeding disorder, paving the way for more active lifestyles (Source: St. Jude Children's Research Hospital)
Source: St. Jude Children's Research Hospital - November 19, 2014 Category: Pediatrics Source Type: news

Hemophilia Causes, Issues and Treatment
'Hemophilia,' refers to a group of inherited disorders that cause bleeding. The bleeding occurs because part of the blood called, 'plasma,' has too little of a protein that helps blood to clot. Symptoms of hemophilia range from increased bleeding after injury, trauma, or surgery to sudden bleeding with no apparent cause. There are 2 types of hemophilia: (Source: Disabled World)
Source: Disabled World - November 14, 2014 Category: Disability Tags: Health and Disability Source Type: news

Hemophilia: Causes, Issues & Treatment
Symptoms of hemophilia range from increased bleeding after injury, trauma, or surgery to sudden bleeding with no apparent cause (Source: Disabled World)
Source: Disabled World - November 14, 2014 Category: Disability Tags: Health and Disability Source Type: news

FDA OKs Drug for Hemophilia A With Factor VIII Inhibitors
Weekly prophylactic treatment associated with substantial decrease in bleeding episodes (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Internal Medicine, Critical Care, Emergency Medicine, Nursing, Oncology, Pathology, Pharmacy, Institutional, Source Type: news

Emicizumab Prophylaxis Cuts Bleeding in Hemophilia A
Lower bleeding rate with administration once weekly, every two weeks versus no prophylaxis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Internal Medicine, Oncology, Journal, Source Type: news

Obizur Antihemophilic Factor (recombinant) for the Treatment of Acquired Haemophilia A
Obizur antihemophilic factor (recombinant) is the first recombinant porcine FVIII indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). (Source: Drug Development Technology)
Source: Drug Development Technology - November 10, 2014 Category: Pharmaceuticals Source Type: news

Falling and fall risk factors in adults with haemophilia: an exploratory study - Sammels M, Vandesande J, Vlaeyen E, Peerlinck K, Milisen K.
Falls are a particular risk in persons with haemophilia (PWH) because of damaged joints, high risk of bleeding, possible impact on the musculoskeletal system and functioning and costs associated with treatment for these fall-related injuries. In addition, ... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - November 1, 2014 Category: Global & Universal Tags: Age: Elder Adults Source Type: news

FDA Approves New Treatment for Hemophilia
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 28, 2014 Category: Journals (General) Source Type: news

Rixubis Recommended by EMA Panel for Hemophilia BRixubis Recommended by EMA Panel for Hemophilia B
Rixubis has been recommended by the European Medicines Agency's Committee for Medicinal Products for Human Use for prophylaxis and treatment of bleeding in patients with hemophilia B. International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 28, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Exclusive: Baxter's new hemophilia drug has its roots in Bala Cynwyd
A new hemophilia treatment has just been approved by the FDA, and it has its roots in the Philadelphia region. The drug is called Obizur, and much of its development was done by Octagen, a Bala Cynwyd, Pa. biotechnology company. The drug is now owned by Baxter International. Acquired hemophilia A is a rare and potentially life-threatening bleeding disorder that, unlike congenital hemophilia, typically affects older adults. It occurs equally in both males and females. Octagen — a company founded… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 27, 2014 Category: American Health Authors: John George Source Type: news

Baxter's blood disorder drug gets FDA approval
(Reuters) - (This Oct. 24 story has been corrected to remove paragraph saying that Obizur will compete with Biogen Idec Inc's BIIB.O Eloctate. Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A) (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Revised Spanish Article-Hemophilia
Hemophilia (heem-o-FILL-ee-ah) is a rare bleeding disorder in which the blood doesn't clot normally. (Source: National Heart, Lung, and Blood Institute Health Topics)
Source: National Heart, Lung, and Blood Institute Health Topics - October 27, 2014 Category: Consumer Health News Source Type: news

New Spanish Article-Hemophilia
New Spanish language article on arrhythmia. (Source: National Heart, Lung, and Blood Institute Health Topics)
Source: National Heart, Lung, and Blood Institute Health Topics - October 27, 2014 Category: Consumer Health News Source Type: news

D.C. Week: ACA Grants Announced, Hemophilia Drug OK'd
(MedPage Today) -- An $840 million initiative to hold down costs. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - October 25, 2014 Category: Geriatrics Source Type: news

New Treatment Approved for Rare Form of Hemophilia
The bleeding disorder affects both males and females Source: HealthDay Related MedlinePlus Page: Hemophilia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - October 24, 2014 Category: Consumer Health News Source Type: news

FDA approves new treatment for rare form of hemophilia
The U.S. Food and Drug Administration yesterday approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVII] deficiency). (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 24, 2014 Category: American Health Source Type: news

Haemophiliacs seek access to new treatment
Group says 350 Hepatitis C patients urgently need new therapies to stay alive (Source: The Irish Times - Health)
Source: The Irish Times - Health - September 15, 2014 Category: Consumer Health News Source Type: news

Using Plant Cells to Help Treat Hemophilia
Accidents as minor as a slip of the knife while chopping onions can turn dangerous for patients with hemophilia, who lack the necessary proteins in their blood to stem the flow from a wound. (Source: Disabled World)
Source: Disabled World - September 5, 2014 Category: Disability Tags: Medical Source Type: news